Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment
Open Access
- 27 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (11), 3079-3091
- https://doi.org/10.1158/0008-5472.can-20-0189
Abstract
This study provides a mechanistic rationale for combining checkpoint blockade immunotherapy with MDM2 inhibitors in patients with wild-type p53 tumors.Other Versions
Funding Information
- Novartis AG | Novartis Institutes for BioMedical Research (N/A)
This publication has 49 references indexed in Scilit:
- RETRACTED ARTICLE: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cellsMolecular Cancer, 2013
- Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanismsEuropean Journal of Immunology, 2011
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion VaccineJournal of Immunotherapy, 2011
- Life or deathCell Cycle, 2010
- Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Tissue expression of PD-L1 mediates peripheral T cell toleranceThe Journal of Experimental Medicine, 2006
- p53 induces TAP1 and enhances the transport of MHC class I peptidesOncogene, 1999
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- p53, guardian of the genomeNature, 1992